Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo.
Scutellarein inhibits RANKL-induced osteoclast formation in vitro and prevents LPS-induced bone loss in vivo.
复制标题
Scutellarein 在体外抑制 RANKL 诱导的破骨细胞形成，并在体内防止 LPS 诱导的骨质流失。
DOI：
10.1002/jcp.27888
复制
发表时间：
2018
影响因子：
5.6
通讯作者：
Xu Jiake
中科院分区：
文献类型：
--
作者：
Fu Fangsheng;Shao Siyuan;Wang Ziyi;Song Fangming;Lin Xixi;Ding Jiaxin;Li Chen;Wu Zuoxing;Li Kai;Xiao Yu;Su Yiji;Zhao Jinmin;Liu Qian;Xu Jiake
骨质疏松症、关节炎、Peget病、骨肿瘤、假体周围关节感染和假体周围松动是骨溶解的共同特征，其特征是破骨细胞性骨吸收功能增强。目前，这些疾病的治疗目标是干扰破骨细胞的形成和功能。灯盏花素(SCU)是一种黄酮类化合物，具有抑制肿瘤进展和炎症的作用。然而，SCU在炎性骨溶解中的作用尚不清楚。我们的研究表明，SCU在体内抑制了脂多糖诱导的骨破坏，在体外抑制了RANKL诱导的OC的形态和功能。机制研究表明，Scu抑制RANKL诱导的破骨细胞标志物基因Ctsk9、Mmp9、Acp5和Atp6v0d2的表达。此外，我们还发现SCU对破骨细胞生成和骨吸收功能的抑制作用是通过减弱NF-κB和NFAT信号通路来实现的。综上所述，SCU有可能成为治疗炎性骨溶解的潜在新药。
Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn’t elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL‐induced, such asCtsk9,Mmp9,Acp5, andAtp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF‐κB and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.